Orforglipron

Orforglipron Orforglipron is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is not a peptide; rather, it’s a small molecule, developed by Eli Lilly to study treatments of obesity in research models. A few researchers have also suggested that Orforglipron is being studied for its ability to potentially treat type 2 diabetes in preclinical models. This compound is being studied in laboratory models in oral tablet form. Sublingual Tablet Options for Research Purposes: You will find Orforglipron for research purposes at our online shop in two different quantities, and here are both: 6mg per tab/90ct/540mg 12mg per tab/90ct/1080mg Chemical Properties PubChem CID 137319706 Structure Molecular Formula C48H48F2N10O5 Synonyms Orforglipron 2212020-52-3 LY3502970 LY-3502970 7ZW40D021M Molecular Weight 883.0 g/mol IUPAC Name 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one CAS 2212020-52-3 Purity ≥95% Stability ≥ 4 years Storage -20°C Researchers conclusion Researchers have found in preclinical models that Orforglipron can be taken with or without food. Safety Requirements in Iabs Make sure to wear proper gloves when carrying out research on this tablet. Dispose of responsibly. Do not dispose of in open drains. Solubility Methanol: Soluble How Does Orforglipron Works? In different research models, Orforglipron has appeared to work by stimulating the GLP-1 (glucagon-like peptide-1) receptor. This key hormone receptor is believed to control blood sugar and appetite regulation in preclinical models. Researchers have found that Orforglipron binds to GLP-1 receptors on pancreatic, brain, and gastrointestinal Orforglipron it binds to these receptors, and Orforglipron may mimic the action of the body’s natural GLP-1 hormone in experimental models. This may help stimulate insulin release from the pancreas when blood glucose is high. It may also suppress glucagon, which reduces excess sugar production by the liver as observed in preclinical models. Furthermore, Orforglipron slows stomach emptying, which helps food stay longer in the gut. A few preliminary studies have also suggested that Orforglipron acts on the brain’s appetite centers in experimental models. Research Application of Orforglipron Orforglipron is used by researchers study metabolic diseases in experimental models. The compound is being studied for weight management and obesity in preclinical models. It is also being investigated in research models for glycemic control in type 2 diabetes, improving HbA1c and fasting glucose levels. Studied in preclinical research to understand GLP‑1 receptor pathways and appetite regulation. Note : Orforglipron not FDA-approved for human consumption. The compound is strictly for research purposes. Why Buy Orforglipron from Purerawz? Purerawz is a good place to buy any research compound because of its authenticity. Orforglipron is one of the top-selling research chemicals. Researchers buy Orforglipron online from Purerawz due to its supreme quality and reliable testing. Additionally, our shipping process and hassle-free secure transactions allow researchers buy Orforglipron conveniently. Disclaimer This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By ordering, you agree to our Terms and Conditions . If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human use Reference Links Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., Allen, S. E., Ahmad, N. N., & Klise, S. R. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2511774 Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in a successful Phase 3 trial | Eli Lilly and Company. (2024). Eli Lilly and Company. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically Dutta, D., Lakshmi Nagendra, Anne B., Kumar, M., Sharma, M., & A. B. M. Kamrul‐Hasan. (2024). Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis. Obesity Science & Practice, 10(2). https://doi.org/10.1002/osp4.743